Fully activated innate immune cells are required for effective responses to infection, but their prompt deactivation and removal are essential for limiting tissue damage. Here, we have identified a critical role for the prolyl hydroxylase enzyme Phd2 in maintaining the balance between appropriate, predominantly neutrophil-mediated pathogen clearance and resolution of the innate immune response. We demonstrate that myeloid-specific loss of Phd2 resulted in an exaggerated inflammatory response to Streptococcus pneumonia, with increases in neutrophil motility, functional capacity, and survival. These enhanced neutrophil responses were dependent upon increases in glycolytic flux and glycogen stores. Systemic administration of a HIF-prolyl hydroxylase inhibitor replicated the Phd2-deficient phenotype of delayed inflammation resolution. Together, these data identify Phd2 as the dominant HIF-hydroxylase in neutrophils under normoxic conditions and link intrinsic regulation of glycolysis and glycogen stores to the resolution of neutrophil-mediated inflammatory responses. These results demonstrate the therapeutic potential of targeting metabolic pathways in the treatment of inflammatory disease.
Abstract Purpose We previously showed that an anti‐PlGF antibody (5D11D4) inhibits choroidal neovascularization (CNV) in a mouse model of AMD. An additive effect was shown in combination therapy with an anti‐VEGFR antibody. Specificity of 5D11D4 was assessed in this study. Methods CNV was induced in mice by placing 3 laser burns on the choroid. Mice with a PlGF deficiency or a lacking tyrosin kinase domain of the Flt‐1R or with a knock‐down of the monocyte chemoattractive protein were generated. The optimal dose of 25mg/kg of 5D11D4 was injected in all mice ip. 3 times a week. Results In a first experiment, loss of PlGF inhibited CNV. However, administration of 5D11D4 to PlGF‐/‐ mice did not inhibit CNV further than in control‐treated PlGF‐/‐ mice, indicating that 5D11D4 did not have off‐target effects. Second, Ccl2‐/‐ mice developed a CNV lesion that was slightly larger than in WT mice within 14 days after laser‐injury. Notably, 5D11D4 was able to inhibit CNV again by 53%. Third, we investigated whether PlGF signaling works specifically through Flt1 in CNV. FITC‐dextran perfused flatmounts revealed that CNV lesions were indeed reduced by 70% in Flt1‐TK‐/‐ mice, comparably as observed in PlGF‐/‐ mice. 5D11D4 was unable to inhibit CNV in Flt1‐TK‐/‐ mice any further. Fourth, we also tested the murine anti‐human PlGF mAb 16D3 in humanized PlGF‐/‐ mice. Human PlGF‐2 increased laser‐induced CNV after 5 days, but this increase was again blocked by 16D3. And finally, of two other anti‐mPlGF mAbs, 3C7A8 and 12H6B6, the first one inhibited CNV, while 12H6B6 was ineffective Conclusion We have proven that 5D11D4 specifically inhibits laser‐induced CNV formation, in different transgenic models and that this effect is mediated via the Flt1 receptor.
Abstract Inhibition of tumor angiogenesis emerged as valuable strategy to treat cancer and has revolutionized the face of clinical oncology by prolonging the life of numerous cancer patients. However, the duration of this response is rather short and tumors rapidly evade treatment, leaving antiangiogenic treatment thus far unable to cure cancer. Hence, novel targets are needed to diversify antiangiogenic treatments and to overcome resistance. Recent data support the concept that tumor infiltration by bone marrow-derived myeloid cells confers resistance to current antiangiogenic drugs targeting primarily vascular endothelial growth factor (VEGF). In this review, we will summarize (pre)clinical data on the role of PlGF and its receptor VEGFR-1 in promoting angiogenesis and inflammation, and the “antimyeloangiogenic” activity of an antibody against PlGF (αPlGF), which may help to overcome resistance against VEGF(R)Is. Because of these promising results, a humanized αPlGF antibody (TB403) is currently evaluated in different phase I clinical trials in cancer patients.
White matter (WM) lesions in preterm newborns may lead to cerebral palsy. To study WM lesions in a mouse model, we used intrapallial stereotactic injections of ibotenic acid, an N-methyl-D-aspartate receptor agonist. Previous studies support a contribution of tissue-type plasminogen activator (t-PA) to the brain lesions seen in various adult excitotoxic models. Therefore, we studied both 5-day-old (P5) wild-type mice and t-PA knock-out (t-PA-/-) mice. The ibotenic acid doses required to induce WM cysts were lower in the wild-type mice (EC50 < 0.01 microg/animal) than in the t-PA-/- mice (EC50 = 2.5 microg/animal) (p < 0.01), indicating the existence of t-PA-dependent and t-PA-independent mechanisms. Dose-dependent prolonged cyst growth occurred in the wild-type mice only. Early microglial activation and astrogliosis were similar in the wild-type and t-PA-/- mice. In adult mice (P45), demyelination occurred at the injection site in both groups but the astroglial scar was denser in the wild-type than in the t-PA-/- mice. These data support involvement of t-PA at several stages of WM lesion formation. Inactivation of t-PA might confer protection by prolonged hemostasis. The role of t-PA in cyst expansion suggests a new approach to the development of neuroprotective strategies in infants with developing WM lesions.